Fig. 6.

ZBED2 represses pancreatic progenitor lineage identity in PDA. (A–C) TF expression in molecular subtypes of PDA. TFs are ranked by their mean log₂ fold-change in Basal-like vs. classic (A and C) or bquamous vs. progenitor (B) patient samples from the indicated studies. (D–F) ZBED2 expression in PDA patient samples stratified according to molecular subtype. Each dot represents one patient sample. P value was calculated using Student’s t test. (G) GSEA evaluating the progenitor PDA Identity signature upon ZBED2 cDNA expression in 15 PDA cell lines. (H and I) GSEA plots evaluating the progenitor-PDA Identity signature following expression of ZBED2 (H) or IRF1 (I) in AsPC1 cells. (J) Overlap of progenitor PDA identity genes with protein coding genes associated with IRF1/ZBED2 sites. (K) ChIP-seq profiles of IRF1 and FLAG-ZBED2 at the promoter of GATA6 in AsPC1 cells. (L) Overlap of leading edge (LE) genes associated with IRF1/ZBED2 sites that are repressed by ZBED2 or activated by IRF1 in AsPC1 cells. (M) Quantification of colony size in Matrigel assays. Means + SEM are shown. n = 3. Representative images at day 7 are shown (Right). (N) Quantification of scratch assays at the indicated time points postseeding and representative images (Right). (Scale bar, 500 μm.) Means + SEM are shown. n = 3. ***P < 0.001, **P < 0.01 *P < 0.05 by Student’s t test; ns, not significant. See also SI Appendix, Fig. S6.